Tremelimumab US Priority Review for Imfinzi combo
25 April 2022 07:00 BST Tremelimumab accepted under Priority Review in the US for patientswith unresectable liver cancer in combination with Imfinzi STRIDE regimen of a single priming dose of tremelimumab added to Imfinzi is the first dual immune checkpoint blockade regimen to improve overall survival in a Phase III trial in this setting AstraZeneca's Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single priming dose of the anti-CTLA4 antibody added to Imfinzi (durvalumab) for the treatment of